Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study | Oncotarget
Therapeutics targeting the fibrinolytic system | Experimental & Molecular Medicine
Urokinase Receptor - an overview | ScienceDirect Topics
Q1iv / 21B19: Outline the process of fibrinolysis (40% marks). Write short notes on the indications, mechanism of action, pharmacokinetics and side effects of tranexamic acid (60% marks) | Jenny's Jam Jar
Urokinase pathway model. (A) Representation of the unperturbed... | Download Scientific Diagram
Frontiers | Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
JaypeeDigital | eBook Reader
Thrombolytics | Concise Medical Knowledge
Frontiers | Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
Thrombolytic (Fibrinolytic) Agents | Mutalik Pharmacology
Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke | PLOS ONE
Tissue and Exosomal Serine Protease Inhibitors Are Significantly Overexpressed in Chronic Rhinosinusitis With Nasal Polyps - S. K. Mueller, A. L. Nocera, S. T. Dillon, T. A. Libermann, O. Wendler, B. S. Bleier, 2019
Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview - Mekkawy - 2014 - Medicinal Research Reviews - Wiley Online Library
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer - ScienceDirect
Cancers | Free Full-Text | Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy
Urokinase - Wikipedia
Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity | SpringerLink
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr - ppt video online download
16.5G: Fibrinolysis - Medicine LibreTexts
Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS | Journal of Intensive Care | Full Text
Mechanism of action of Nattokinase. Nattokinase dissolves blood clots by directly hydrolyzing fibrin and plasmin. It converts endogenous prourokinase to urokinase (uPA). Additionally, it degrades plasminogen activator inhibitor (PAI-1) and increases the
Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues: Trends in Biochemical Sciences
Thrombolytics | Concise Medical Knowledge
CV Pharmacology | Thrombolytic (Fibrinolytic) Drugs
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke | SpringerLink
Computational model of tranexamic acid on urokinase mediated fibrinolysis | PLOS ONE
